Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.
Chronic Disease
/ drug therapy
Clinical Trials, Phase III as Topic
Delayed-Action Preparations
/ administration & dosage
Dose-Response Relationship, Drug
Drug Implants
/ administration & dosage
Drug Liberation
Fluocinolone Acetonide
/ administration & dosage
Glucocorticoids
/ administration & dosage
Humans
Randomized Controlled Trials as Topic
Treatment Outcome
Uveitis, Posterior
/ drug therapy
YUTIQ™
fluocinolone acetonide
intravitreal corticosteroid implant
noninfectious uveitis
posterior uveitis
sustained-release drug delivery system
Journal
Therapeutic delivery
ISSN: 2041-6008
Titre abrégé: Ther Deliv
Pays: England
ID NLM: 101538870
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
31
10
2019
medline:
9
6
2020
entrez:
31
10
2019
Statut:
ppublish
Résumé
Uveitis is a major cause of ocular morbidity, potentially leading to significant visual impairment. The recent adoption of alternative drug delivery options has led to the development of new sustained-delivery corticosteroid systems, able to manage successfully chronic noninfectious posterior uveitis. The treatment goal is to target the site of inflammation with low dose of corticosteroids, delivered over an extended period of time, to minimize the cumulative damage resulting from repeated recurrences, reducing both injections frequency and ocular side effects. This article will review the pharmacology and preliminary clinical data of the 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ™), to show its efficacy and safety in the treatment of noninfectious posterior uveitis.
Identifiants
pubmed: 31663454
doi: 10.4155/tde-2019-0051
pmc: PMC6880290
doi:
Substances chimiques
Delayed-Action Preparations
0
Drug Implants
0
Glucocorticoids
0
Fluocinolone Acetonide
0CD5FD6S2M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-625Références
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Ophthalmology. 1985 Apr;92(4):467-71
pubmed: 4000641
Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
pubmed: 15019324
Ophthalmology. 2005 Jul;112(7):1192-8
pubmed: 15921758
J Ocul Pharmacol Ther. 2015 Feb;31(1):11-6
pubmed: 25562126
Ophthalmology. 2019 Apr;126(4):601-610
pubmed: 30367884
Invest Ophthalmol Vis Sci. 2013 Jul 18;54(7):4864-70
pubmed: 23761087
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75
pubmed: 11006254
Arch Ophthalmol. 2011 May;129(5):545-53
pubmed: 21220619
J Ocul Pharmacol Ther. 2004 Jun;20(3):269-75
pubmed: 15279731
Int Ophthalmol Clin. 2005 Spring;45(2):1-13
pubmed: 15791154
Medicine (Baltimore). 2001 Jul;80(4):263-70
pubmed: 11470987
Ophthalmology. 2013 Mar;120(3):583-587
pubmed: 23218184
Postgrad Med J. 2017 Dec;93(1106):766-773
pubmed: 28942431